This session focuses on new antidiabetic agents, how these drugs affect the renal system, and specific considerations for patients in advanced stages of chronic kidney disease (CKD) who take these drugs. The impact of hypoalbuminuria on the pharmacokinetics and pharmacodyanmics of antidiabetic agents is also discussed.
You must be logged in and own this session in order to post comments.